Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine · 02.01.2025 · 392 (1) · 45-55
DOI: 10.1056/nejmoa2401726 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.01.2025. Verfasst von Andrea B Apolo und 39 weiteren Autor:innen. Beteiligte Einrichtung: From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Transitional Cell, Neoplasm Invasiveness. Die Arbeit wurde bisher 169-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C…
ORCID-Profile: Andrea B Apolo
Förderung
- NCATS NIH HHS
- NCI NIH HHS
- Intramural NIH HHS
- National Cancer Institute of the National Institutes of Health
- Merck
- Center for Cancer Research
- National Cancer Institute Intramural Program
- Cancer Therapy Evaluation Program
Zitieren
APA
Apolo, A. B., Ballman, K. V., Sonpavde, G., Berg, S., Kim, W. Y., Parikh, R., Teo, M. Y., Sweis, R. F., Geynisman, D. M., Grivas, P., Chatta, G., Reichert, Z. R., Kim, J. W., Bilen, M. A., McGregor, B., Singh, P., Tripathi, A., Cole, S., Simon, N., …, & Rosenberg, J. E. (2025). Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. New England Journal of Medicine, 392(1), 45-55. https://doi.org/10.1056/nejmoa2401726
Vancouver
Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, et al. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. New England Journal of Medicine. 2025;392(1):45-55. doi:10.1056/nejmoa2401726
BibTeX
@article{Apolo2025,
author = {Apolo, Andrea B and Ballman, Karla V and Sonpavde, Guru and Berg, Stephanie and Kim, William Y and Parikh, Rahul and Teo, Min Yuen and Sweis, Randy F and Geynisman, Daniel M and Grivas, Petros and Chatta, Gurkamal and Reichert, Zachery Roger and Kim, Joseph W and Bilen, Mehmet Asim and McGregor, Bradley and Singh, Parminder and Tripathi, Abhishek and Cole, Suzanne and Simon, Nicholas and Niglio, Scot and Ley, Lisa and Cordes, Lisa and Srinivas, Sandy and Huang, Jiaoti and Odegaard, Meagan and Watt, Colleen and Petrylak, Daniel and Hoffman-Censits, Jeannie and Wen, Yujia and Hahn, Olwen and Mitchell, Cecilia and Tan, Alan and Streicher, Howard and Sharon, Elad and Moon, Helen and Woods, Michael and Halabi, Susan and Perez Burbano, Gabriela and Morris, Michael J and Rosenberg, Jonathan E},
title = {Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {1},
pages = {45--55},
doi = {10.1056/nejmoa2401726}
}
EUVIMED